OGT Licenses Patents to Biotype Diagnostics for Microarray Technology Development
November 22, 2010
OGT Licenses Patents to Biotype Diagnostics for Microarray Technology Development
According to Biotype's executive director, the patents will help the company "develop our own microarray technology platform for various applications in medicine and analytics."
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- OGT Inks Deal with CCMC to Build Cancer Microarray
February 26, 2013 / GenomeWeb Daily News - Agilent, OGT Expand Partnership to Include Oligonucleotide Microarrays, SureSelect Products
October 17, 2011 / GenomeWeb Daily News - Platform Comparison Study Favors Higher-Density Chromosomal Microarrays for AOH Detection
April 9, 2013 / BioArray News - OGT's Protein Array at Heart of Sengenics Deal, Test-Development Programs
March 19, 2013 / BioArray News - In Bid to Court Cancer Cyto Community, OGT Prepares CCMC-Designed Chip for Launch
February 26, 2013 / BioArray News